Old formula of Levothyrox available in France in 2019Le Parisien reported on Tuesday (p.12) that the old formula of Levothyrox, Euthyrox, will be available in France next year. (APMHE 60466)
Supply issues for blood-based drugsLa Croix reported on Monday (p.11) in a brief that some blood-based drugs manufactured by the French pharma Laboratoire français du fractionnement et des biotechnologies (LFB), are undergoing supply problems (APMHE 60452).
Increasing shortagesLa Croix reports on Friday (p.7) on the ongoing drug shortages in France, particularly the alert raised by the patient association France Parkinson regarding Merck Sharp & Dohme’s Parkinson's drug, Sinemet.
Sanofi benefiting from Chinese healthcare reformLes Echos reports on Friday (p.16) that Sanofi is benefiting from the Chinese government’s healthcare reform, which is making it easier for innovative and high-quality drugs to get market access.
Pharmacists not dispensing substitution drugsSeventy percent of Parisian pharmacists are not dispensing substitution drugs to former drug addicts, according to the French drug users’ self-help association (Asud), reported L’Humanité on Monday (p.14). This is despite the former drug addicts having prescriptions.
MAb114, the drug 'made in Congo' to treat EbolaLe Monde Eco & Entreprise ran an article on Wednesday (p.2) on the history of mAb114, the Ebola drug “made in Congo”. After over 20 years in development, the drug has been administered to 42 patients since August.
Potential cure for endometriosisLe Point reported on Thursday (p.24) that researchers at the University of Chicago had shown it is possible to programme stem cells to create healthy uterine cells. A way to implant these cells into the uterus and replace defective cells now needs to be found.
French biotech gets second round of fundingLes Echos reported on Thursday (p.27) that the French biotech C4Diagnostics had succeeded in getting a second round of funding for a kit to diagnosis legionella bacteria, which cause legionnaires’ disease, in 48 hours instead of the usual seven days.
AI in diagnosisLa Croix ran a feature on Tuesday (p.13-15) on the role of artificial intelligence (AI) in diagnosing diseases, especially cancers, and the issues surrounding it, particularly the ethical issue of whether or not AI could replace a human doctor.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.